About Us | Site Map | Contact Us

COVID-19- Home

small logo

The Corona Virus - Info and Links

This page is the COVID-19 information site where you can find links to websites and documents about the virus known as COVID19 or The Wuhan Virus, as some have come to call it.

I will provide detailed documentation from government agencies, pharmaceutical companies, and independent researchers qualified to speak on the matter. Much of this information is laboratory reports, clinical trial reports, and actual data on the origins of the vaccine and how it came to fruition so quickly.

Data collected from clinical trials and reports turned in by patients who suffered symptoms (some serious) are also found within these pages.

The Official Story

Although the exact origin of the virus is still unknown,[9] the first outbreak started in Wuhan, Hubei, China in late 2019. Many early cases of COVID-19 were linked to people who had visited the Huanan Seafood Wholesale Market in Wuhan,[10][11][12] but it is possible that human-to-human transmission was already happening before this.[13][14] On 11 February 2020, the World Health Organization (WHO) named the disease "COVID-19", which is short for coronavirus disease 2019.[15][16] The virus that caused the outbreak is known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly discovered virus closely related to bat coronaviruses,[17] pangolin coronaviruses,[18][19] and SARS-CoV.[20] The current scientific consensus is that the virus is most likely of zoonotic origin, from bats or another closely-related mammal.[21][22][23][13] Despite this, the subject has generated a significant amount of speculation and conspiracy theories,[24][14] which were amplified by rapidly growing online echo chambers.[25] Global geopolitical divisions, notably between the United States and China, have been heightened because of this issue.[26][27][28]

The earliest known person with symptoms was later discovered to have fallen ill on 1 December 2019, and that person did not have visible connections with the later wet market cluster.[29][30] However, an earlier case of infection could have occurred on 17 November.[31] Of the early cluster of cases reported that month, two thirds were found to have a link with the market.[32][33][34] There are several theories about when and where the very first case (the so-called patient zero) originated.


Official case counts refer to the number of people who have been tested for COVID-19 and whose test has been confirmed positive according to official protocols.[36][37] Many countries, early on, had official policies to not test those with only mild symptoms.[38][39] An analysis of the early phase of the outbreak up to 23 January estimated 86 percent of COVID-19 infections had not been detected, and that these undocumented infections were the source for 79 percent of documented cases.[40] Several other studies, using a variety of methods, have estimated that numbers of infections in many countries are likely to be considerably greater than the reported cases.[41][42]

On 9 April 2020, preliminary results found that 15 percent of people tested in Gangelt, the centre of a major infection cluster in Germany, tested positive for antibodies.[43] Screening for COVID-19 in pregnant women in New York City, and blood donors in the Netherlands, has also found rates of positive antibody tests that may indicate more infections than reported.[44][45] Seroprevalence based estimates are conservative as some studies show that persons with mild symptoms do not have detectable antibodies.[46] Some results (such as the Gangelt study) have received substantial press coverage without first passing through peer review.[47]

An analysis in early 2020 of cases by age in China indicated that a relatively low proportion of cases occurred in individuals under 20.[48] It was not clear whether this was because young people were less likely to be infected, or less likely to develop serious symptoms and seek medical attention and be tested.[49] A retrospective cohort study in China found that children and adults were just as likely to be infected.[50]

Initial estimates of the basic reproduction number (R0) for COVID-19 in January were between 1.4 and 2.5,[51] but a subsequent analysis concluded that it may be about 5.7 (with a 95 percent confidence interval of 3.8 to 8.9).[52] R0 can vary across populations and is not to be confused with the effective reproduction number (commonly just called R), which takes into account effects such as social distancing and herd immunity. By mid-May 2020, the effective R was close to or below 1.0 in many countries, meaning the spread of the disease in these areas at that time was stable or decreasing.[

Official deaths from COVID-19 generally refer to people who died after testing positive according to protocols. These counts may ignore deaths of people who die without having been tested.[55] Conversely, deaths of people who had underlying conditions may lead to over-counting.[56] Comparisons of statistics for deaths for all causes versus the seasonal average indicate excess mortality in many countries.[57][58] This may include deaths due to strained healthcare systems and bans on elective surgery.[59] The first confirmed death was in Wuhan on 9 January 2020.[60] The first reported death outside of China occurred on 1 February in the Philippines,[61] and the first reported death outside Asia was in the United States on 6 February.[62]

More than 95 percent of the people who contract COVID-19 recover. Otherwise, the time between symptoms onset and death usually ranges from 6 to 41 days, typically about 14 days.[63] As of 2 June 2021, more than 3.68 million[3] deaths have been attributed to COVID-19. People at the greatest risk of mortality from COVID-19 tend to be those with underlying conditions, such as those with a weakened immune system, serious heart or lung problems, severe obesity, or the elderly (including individuals age 65 years or older).[64][65]

Multiple measures are used to quantify mortality.[66] These numbers vary by region and over time, influenced by testing volume, healthcare system quality, treatment options, government response,[67][68][69] time since the initial outbreak, and population characteristics, such as age, sex, and overall health.[70] Countries like Belgium include deaths from suspected cases of COVID-19, regardless of whether the person was tested, resulting in higher numbers compared to countries that include only test-confirmed cases.[71]

The death-to-case ratio reflects the number of deaths attributed to COVID-19 divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 2.1 percent (3,683,428 deaths for 171,335,846 cases) as of 2 June 2021.[3] The number varies by region.[72]

The official death counts have been criticized for underreporting the actual death toll, because comparisons of death rates before and during the pandemic show an increase in deaths that is not explained by COVID-19 deaths alone.[73] Using such data, estimates of the true number of deaths from COVID-19 worldwide have included a range from 7 to 13 million by The Economist, as well as over 9 million by the Institute for Health Metrics and Evaluation.[73][74]

Next page

Latest COVID-19 Information


COVID-19 RNA Based Vaccines and the Risk of Prion Disease - J. Bart Classen, MD

In this peer reviewed paper, J. Bart Classen M.D. warns about the COVID-19 vaccine and the possibility that it may be making patients sicker than what they experience with COVID-19. There are nineteen references in his paper than deal with the COVID-19 vaccine, mRNA and vaccine adverse reactions. Go there. This is one of the best papers you can read on the subject.


COVID-19,MMR,and Vaccine Bioweapons

In this paper, Bart Classen MD makes the case that the COVID19 vaccine is a bioweapon based on the observations of doctors in the field who have witnesses diseases that act like bioweapons. Dr. Classen speaks to the fact that a vaccine called; "MMR" seems to help with COVID19, suggesting that its development before the outbreak of COVID19 is to treat certain people. Read it here. Classen suggests that further research and observation are prudent to determine if the MMR vaccine does indeed help and determine what the government knew beforehand about the vaccine's success in treating COVID19.


The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease

Startlingly, these RNA-binding prion candidates are inexorably emerging, one by one, in the pathology and genetics of devastating neurodegenerative disorders, including: amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U), Alzheimer's disease and Huntington's disease. For example, FUS and TDP-43, which rank 1 st and 10 th among RRM-bearing prion candidates, form cytoplasmic inclusions in the degenerating motor neurons of ALS patients and mutations in TDP-43 and FUS cause familial ALS. Recently, perturbed RNA-binding proteostasis of TAF15, which is the 2 nd ranked RRM-bearing prion candidate, has been connected with ALS and FTLD-U. We predict that additional RNA-binding prion candidates identified by our algorithm will soon surface as genetic modifiers or causes of diverse neurodegenerative conditions.


Review of COVID-19 Vaccines and the Risk of Chronic Adverse Events Including Neurological Degeneration

Many have argued that the outbreak of COVID-19 is the result of the release of a viral based bioweapon. Vaccines to COVID-19 have been developed and a policy of universal immunization has been initiated with total disregard to the fact that the virus may be a bioweapon. The potential risk of a catastrophe exists in part because all the vaccines contain the spike protein and or the mRNA/DNA encoding for the COVID-19 associated spike protein. Read it here. These vaccines were designed and placed on the market with little knowledge of how the spike protein or its nucleic acid causes disease and without knowledge of long-term adverse effects of the vaccines.


Can COVID-19 Induce an Autoimmune Disease Associated with Long-Lasting Symptoms and Delayed Complications?

A subset of patients with Covid-19 develops late clinical symptoms or severe complications, with thromboinflammation affecting microcirculation and many organs, in addition to the acute severe respiratory syndrome. Complications occur when neutralizing antibodies are already present and the viral load is low or undetectable. Read it here We hypothesized that the SARS-CoV-2 high affinity binding to ACE2 through its spike protein RBD can induce a spreading of the immune response to the self-components involved in this cell entry complex, and especially to ACE2.


Creutzfeldt-Jakob disease in a man with COVID-19:SARS-CoV-2-accelerated neurodegeneration?

We describe a man whose first manifestations of Creutzfeldt-Jakob disease occurred in tandem with symptomatic onset of coronavirus disease 2019 (COVID-19). Drawing from recent data on prion disease pathogenesis and immuneresponses to SARS-CoV-2, we hypothesize that the cascade of systemic inflammatory mediators in response to the virus accelerated the pathogenesis of four patients prion disease. Read it here. This hypothesis introduces the potential relationship between immuneresponses to the novel coronavirus and the hastening of preclinicalor manifest neurodegenerative disorders.

valid-xhtml11-blue.pngvalid-xhtml11-blue.png About Us | Site Map | Privacy Policy | Contact Us | ©2021 Outwest Productions